We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Unanswered Questions and Warnings Involving Anti--Immunoglobulin E Therapy Based on 2-Year Observation of Clinical Experience.
- Authors
Lanier, Bob Q.
- Abstract
The relatively rapid development and deployment of a clinically useful monoclonal antibody omalizumab has produced a number of questions still not answered despite massive research and many clinical trials. The mechanism of action as down-regulation of FceRl receptors in the presence of low free immunoglobulin E (IgE) is incomplete. Some severe allergic asthmatic patients respond almost immediately, others take months, and some never respond. No accounting for the possible antigen sweeping by the complexes of IgG-IgE has been reported. Skin tests may remain positive for much longer than reported, raising the possibility of anaphylaxis with concomitant specific immunotherapy. Two cases of anaphylaxis to specific immunotherapy while being "covered" with anti-IgE are reported. Total IgE levels do not always rise as expected, six cases of static IgE levels in responders are reported.
- Publication
Allergy & Asthma Proceedings, 2005, Vol 26, Issue 6, p435
- ISSN
1088-5412
- Publication type
Academic Journal